SKYE
Skye Bioscience, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 15 ▼ Skye Bioscience received a Nasdaq delisting notice on May 13, 2026,…
- Aug 14 Skye Bioscience (SKYE) entered into a definitive transaction agreeme…
- Aug 14 ▼ Skye Bioscience announces a reverse merger with private UK biotech R…
- Aug 14 Activist stake: Skye Bioscience and Redx Pharma Announce Transaction Agree…
- Aug 14 Trading halt: Trading Halt: SKYE, T1 (News Pending)
- Aug 18 to Aug 20 ▼ 3 days of insider sells: $280.6K by 2 insiders, avg $0.3733
- Aug 21 Trading halt: Trading Halt: SKYE, T1 (News Pending)
- Aug 31 ▲ Short interest falls 89.3% to 128.8K
- Sep 16 to Sep 23 ▼ 3 days of insider sells: $608.6K by 2 insiders, avg $1.67
- Sep 24 ▼ 5AM Partners VII, LLC and affiliated entities filed Amendment No. 6…
- Sep 30 ▼ Short interest jumps 26.4% to 148.0K
- Oct 26 ▼ Skye Bioscience (SKYE) filed a preliminary proxy statement (PREM14A)…
- Nov 13 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $889.2K.
- InstitutionsMIXED
Q2 2026: 2 added (0 new), 3 trimmed or exited.
- Short sellersSTEADY
Short interest −7.8% to 129.3K shares. 6.3 days to cover, ≈2.9% of shares.
- TrendDOWNTREND
31% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | ADD | $51.1K |
| NORTHERN TRUST CORP | DOUBLED | $39.1K |
| GROUP ONE TRADING LLC | TRIM | $3.2K |
| BARCLAYS PLC | NEAR_EXIT | $455.00 |
| TD Waterhouse Canada Inc. | TRIM | $35.00 |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $170.4K |
| MILLENNIUM MANAGEMENT LLC | TRIM | $158.7K |
| UBS Group AG | DOUBLED | $28.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Sep 2025| Date | Firm | Rating |
|---|---|---|
| Sep 30, 2025 | HC Wainwright & Co. INITIATE | Buy |
| Aug 15, 2025 | Evercore ISI Group INITIATE | Outperform |
| Jun 24, 2025 | JMP Securities REITERATE | Market Outperform |
| Mar 21, 2025 | Craig-Hallum MAINTAIN | Buy |
| Mar 21, 2025 | Citizens Capital Markets REITERATE | Market Outperform |
| Feb 28, 2025 | William Blair INITIATE | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Schwab Andrew J. Director Sep 23, 2026 | SELL | $184.9K |
Schwab Andrew J. Director Sep 23, 2026 | SELL | $7.3K |
5AM Partners VII, LLC 10%+ Owner Sep 23, 2026 | SELL | $184.9K |
5AM Partners VII, LLC 10%+ Owner Sep 23, 2026 | SELL | $7.3K |
Schwab Andrew J. Director Sep 22, 2026 | SELL | $45.6K |
Schwab Andrew J. Director Sep 22, 2026 | SELL | $1.8K |
5AM Partners VII, LLC 10%+ Owner Sep 22, 2026 | SELL | $45.6K |
5AM Partners VII, LLC 10%+ Owner Sep 22, 2026 | SELL | $1.8K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026| Nov 10, 2026 | Volatility Pause | Resumed |
| Aug 21, 2026 | Resumption Scheduled | Resumed |
| Aug 14, 2026 | Volatility Pause | Resumed |
| Aug 14, 2026 | Resumption Scheduled | Resumed |
SecBot reports
13 filings · 3 press releases · 0 bullish · 5 bearish · 1 mixed · 7 neutral- NEUTRAL DEFA14ANov 12, 2026
Skye Bioscience filed a DEFA14A disclosing a unanimous jury verdict in its favor in a former…
Monitor for post-trial motions or appeal by plaintiff; the Redx acquisition proxy vote and Nasdaq listing status are the next key catalysts for this micro-cap.
- NEUTRAL 8-KNov 12, 2026
Skye Bioscience disclosed that a jury returned a unanimous verdict in favor of the company on all…
The company has no current liability from this lawsuit. Monitor for any post-trial motions or appeal filings by the plaintiff, which could reintroduce uncertainty.
- BEARISH PREM14AOct 26, 2026
Skye Bioscience (SKYE) filed a preliminary proxy statement (PREM14A) seeking stockholder approval…
Monitor the resolution of the Specified Adjustment, which could reduce Skye's valuation to $2 million and further dilute existing holders to 0.78%. Watch for Nasdaq listing approval for the combined…
- NEUTRAL SC 13GOct 14, 2026
Tang Capital Management, LLC and affiliated entities (Kevin Tang) filed a Schedule 13G disclosing…
Monitor for any subsequent conversion of this 13G to a 13D, which would signal activist intent. Kevin Tang has a history of taking positions in small-cap biotechs and pushing for strategic…
All SKYE filing & press-release reports (16)
- DEFA14A reportNov 12, 2026
- 8-K reportNov 12, 2026
- PREM14A reportOct 26, 2026
- SC 13G reportOct 14, 2026
- CLUSTER reportSep 24, 2026
- SC 13D/A reportSep 24, 2026
- CLUSTER reportSep 18, 2026
- DEFA14A reportAug 19, 2026
- 8-K reportAug 14, 2026
- PRESS-RELEASE reportAug 14, 2026
- 8-K reportMay 15, 2026
- PRESS-RELEASE reportMay 12, 2026
- 3 reportApr 28, 2026
- DEFA14A reportApr 16, 2026
- PRESS-RELEASE reportApr 2, 2026
- PRESS-RELEASE reportMar 10, 2026